{"disease":{"id":"polyneuropathy-in-amyloidosis","name":"Polyneuropathy in amyloidosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"patisiran","indication_name":"Polyneuropathy in amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onpattro","generic_name":"PATISIRAN","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":59,"revenue":"700","mechanism":"Onpattro works by silencing the production of abnormal TTR protein using small interfering RNA."},{"drug_id":"patisiran-sodium","indication_name":"Polyneuropathy in amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onpattro","generic_name":"PATISIRAN SODIUM","company_name":"Alnylam Pharmaceuticals","drug_phase":"marketed","molecular_target":"transthyretin (TTR) mRNA","drug_class":"Small Interfering RNA","quality_score":10,"revenue":"700","mechanism":"Onpattro works by silencing the production of abnormal TTR protein through RNA interference."},{"drug_id":"eplontersen","indication_name":"Polyneuropathy of hereditary transthyretin-mediated amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wainua","generic_name":"EPLONTERSEN","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Transthyretin-directed RNA Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein."},{"drug_id":"eplontersen","indication_name":"polyneuropathy of hereditary transthyretin-mediated amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wainua","generic_name":"EPLONTERSEN","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Transthyretin-directed RNA Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01737398","title":"Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05940922","title":"RWE-based Treatment Patterns and Outcomes in CIDP","phase":"","overall_status":"UNKNOWN","enrollment_count":170,"lead_sponsor_name":"RwHealth","has_results":false},{"nct_id":"NCT02175004","title":"Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04601051","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Intellia Therapeutics","has_results":false},{"nct_id":"NCT06539208","title":"A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"YolTech Therapeutics Co., Ltd","has_results":false},{"nct_id":"NCT01604122","title":"Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers","phase":"","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}